Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma
暂无分享,去创建一个
S. Fox | B. Solomon | S. Hendry | D. Rischin | A. Thai | M. Bressel | M. Kowanetz | R. Young | J. Corry | T. Fua | D. Urban | C. Angel | A. Haddad | R. J. Young
[1] V. Budach,et al. The PD‐1/PD‐L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK‐ROG) , 2017, International journal of cancer.
[2] J. Taube,et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.
[3] K. Harrington,et al. Abstract CT021: Tumor-associated immune cell PD-L1 expression and peripheral immune profiling: Analyses from CheckMate 141 , 2017 .
[4] K. Pitman,et al. Evaluation of proposed staging systems for human papillomavirus‐related oropharyngeal squamous cell carcinoma , 2017, Cancer.
[5] R. Decker,et al. A Comparison of Prognostic Ability of Staging Systems for Human Papillomavirus–Related Oropharyngeal Squamous Cell Carcinoma , 2017, JAMA oncology.
[6] B. Panizza,et al. Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy. , 2017, Oral oncology.
[7] F. Hirsch,et al. PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[8] Su Jin Heo,et al. PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients , 2016, Scientific Reports.
[9] A. Hakimi,et al. The head and neck cancer immune landscape and its immunotherapeutic implications. , 2016, JCI insight.
[10] A. Chaturvedi,et al. Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population. , 2016, Oral oncology.
[11] E. King,et al. Gene expression analysis of TIL rich HPV-driven head and neck tumors reveals a distinct B-cell signature when compared to HPV independent tumors , 2016, Oncotarget.
[12] R. Bourgon,et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.
[13] Keunchil Park,et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial , 2016, The Lancet.
[14] Shao Hui Huang,et al. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. , 2016, The Lancet. Oncology.
[15] Jedd D. Wolchok,et al. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations , 2016, Science Translational Medicine.
[16] D. van Baarle,et al. Differences in T-cell infiltrates and survival between HPV+ and HPV- oropharyngeal squamous cell carcinoma , 2016, Future science OA.
[17] P. Stern,et al. Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma , 2015, British Journal of Cancer.
[18] John Cho,et al. Refining American Joint Committee on Cancer/Union for International Cancer Control TNM stage and prognostic groups for human papillomavirus-related oropharyngeal carcinomas. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Kevin P. White,et al. Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes , 2014, Clinical Cancer Research.
[20] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[21] E. King,et al. Staging and treatment of oropharyngeal cancer in the human papillomavirus era , 2014, Head & neck.
[22] J. Galon,et al. Imaging , Diagnosis , Prognosis Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer , 2014 .
[23] Jacques Ferlay,et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] F. Marincola,et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.
[25] E. King,et al. Tumour-infiltrating lymphocytes predict for outcome in HPV-positive oropharyngeal cancer , 2013, British Journal of Cancer.
[26] T. Nyberg,et al. CD8+ and CD4+ tumour infiltrating lymphocytes in relation to human papillomavirus status and clinical outcome in tonsillar and base of tongue squamous cell carcinoma. , 2013, European journal of cancer.
[27] N. Kokot,et al. Immune cell infiltration patterns and survival in head and neck squamous cell carcinoma. , 2013, Head & neck oncology.
[28] J. Lewis. p16 Immunohistochemistry As a Standalone Test for Risk Stratification in Oropharyngeal Squamous Cell Carcinoma , 2012, Head and Neck Pathology.
[29] H. Johansson,et al. Tumor Infiltrating CD8+ and Foxp3+ Lymphocytes Correlate to Clinical Outcome and Human Papillomavirus (HPV) Status in Tonsillar Cancer , 2012, PloS one.
[30] R. Shaw,et al. Evaluation of Human Papilloma Virus Diagnostic Testing in Oropharyngeal Squamous Cell Carcinoma: Sensitivity, Specificity, and Prognostic Discrimination , 2011, Clinical Cancer Research.
[31] Zlatko Trajanoski,et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] R. Fisher,et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] K. Ang,et al. Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.
[34] A. Cmelak,et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.
[35] Z. Trajanoski,et al. Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.
[36] George Coukos,et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. , 2003, The New England journal of medicine.
[37] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[38] A. Garden,et al. An evolution in demographics, treatment, and outcomes of oropharyngeal cancer at a major cancer center , 2013, Cancer.
[39] Patrice Ravel,et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. , 2013, Cancer research.